Hydrocortisone Treatment for Children With Septic Shock in Pediatric Intensive Care Units
Led by Jerry Zimmerman · Updated on 2025-10-30
500
Participants Needed
44
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the potential benefits and risks of using adjunctive hydrocortisone in children with septic shock that does not respond to fluids and vasoactive medications. The trial aims to determine whether hydrocortisone can reduce the occurrence of new or worsening organ dysfunction and improve outcomes such as survival and quality of life in pediatric patients. This study is a randomized, double-blinded, placebo-controlled trial involving critically ill children in pediatric intensive care units.
Participants are randomly assigned to one of two groups one receives hydrocortisone sodium succinate according to a specific dosing schedule, and the other receives a placebo of normal saline with the same volume and schedule. The hydrocortisone treatment starts with a 2 mgkg intravenous bolus followed by 1 mgkg doses every six hours for up to seven days or until vasoactive medications have been stopped for at least 12 hours. The placebo group receives an identical schedule of saline infusions.
During the study, children will be monitored closely while in the intensive care unit for adverse events such as high blood sugar, gastrointestinal bleeding, delirium, and hospital-acquired infections. Researchers will assess organ dysfunction using the Pediatric Logistic Organ Dysfunction PELOD-2 tool and evaluate health-related quality of life with the Pediatric Quality of Life Inventory PedsQL at 28 days after enrollment. Follow-up assessments will also occur at 90 days. The study plans to enroll up to 500 children from multiple countries, with the goal of improving treatment guidelines for septic shock in children.
CONDITIONS
Brief Title
Stress Hydrocortisone In Pediatric Septic Shock
Research Team
J
Jerry J Zimmerman, MD, PhD
K
Kusum Menon, MD, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Hydrocortisone, sodium succinate
Placebo (normal saline)
What it is
Hydrocortisone, sodium succinate administered as intravenous stress-dose therapy for pediatric septic shock.
Normal saline given intravenously as placebo with identical dosing and schedule.
Role in trial
Investigational arm evaluating hydrocortisone as adjunctive treatment for septic shock in children.
Comparator arm for evaluating outcomes without corticosteroid therapy.
Primary use
Used to assess whether hydrocortisone improves organ dysfunction and survival in pediatric septic shock.
Used to evaluate clinical outcomes without steroid intervention under identical conditions.
How it is given or performed
Initial IV bolus of 2 mg/kg hydrocortisone, followed by 1 mg/kg (maximum 50 mg) every 6 hours for up to seven days or until vasoactive support ends.
Equivalent volume of normal saline IV, administered every 6 hours following same schedule as hydrocortisone arm.
Important risks
Potential adverse effects include hyperglycemia, immunosuppression, hypertension, and risk of infection, as noted in prior pediatric ICU steroid studies.
No disease-specific risks. Standard intravenous saline administration has minimal risks in the pediatric ICU context.
Important limitations
Hydrocortisone evidence for pediatric septic shock is inconclusive. Previous trials have used different populations, dosing regimens, and outcome definitions. Practice varies between institutions.
Placebo-controlled trials provide important safety and efficacy benchmarks, but lack of routine standard comparator limits generalizability to current practice. Practice varies and no established nonsteroid alternative exists for shock refractory to vasoactive support.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 1Month - 17Years
All Genders
Eligibility Criteria
You may qualify if you...
Child is at least 1 month old (corrected gestational age at least 42 weeks) but less than 17 years and 8 months old
Documented or strongly suspected infection at PICU admission or at septic shock onset
Surveillance cultures or microbial tests have been obtained
One or more antimicrobials have been prescribed
Abnormal temperature or white blood cell counts documented within 24 hours before screening
Receiving continuous infusion of vasoactive-inotropic agents to maintain blood pressure
Receiving two or more vasoactive-inotropic agents at any dose or epinephrine/norepinephrine infusion at ≥0.10 mcg/kg/min for over 1 hour
You will not qualify if you...
All inclusion criteria have been present for more than 12 hours
Expected to receive systemic corticosteroids for reasons other than septic shock
Received systemic corticosteroids during sepsis treatment
Enrolled in another interventional clinical trial
Received etomidate or ketoconazole in past 48 hours
Known or suspected hypothalamic, pituitary, or adrenal disease
Care team or guardians not committed to full treatment and resuscitation
Documented pregnancy
Previously enrolled in this study
Thermal burn patient admitted directly to PICU less than 72 hours prior
(U.S. only) Patient in custody of US protective services
Being evaluated for brain death
Vasoactive agents prescribed for causes other than septic shock
Confirmed dengue fever
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 7 days or until vasoactive infusions are discontinued for 12 hours, whichever comes first
Participants receive either hydrocortisone or a placebo through intravenous infusions while in the Pediatric Intensive Care Unit. Treatment lasts up to seven days or until vasoactive infusions have been stopped for at least 12 hours.
Daily monitoring visits while in the Pediatric Intensive Care Unit
Follow-up
Duration - Up to 90 days
Participants are assessed for outcomes including organ dysfunction, mortality, and health-related quality of life at 28 and 90 days after enrollment.
2 follow-up visits at 28 days and 90 days post-enrollment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Fludrocortisone Dosing Trial for Critically Ill Adults with Septic Shock Receiving Hydrocortisone Evaluating Survival and Recovery
Pilot Study of Adding Fludrocortisone to Hydrocortisone Treatment in Adults with Septic Shock to Assess Feasibility of a Large International Trial
Comparing Adrenaline and Dopamine to Treat Fluid Refractory Septic Shock in Children Aged 1 Month to 12 Years
Study of Albumin and Crystalloid Fluids to Improve Survival in Adults with Septic Shock
Study of Aminoglycoside Antibiotics with Continuous Renal Replacement Therapy in Adults With Sepsis or Septic Shock and Kidney Impairment
ARTISTRY Registry Study for ARTICE4 Therapy Use in Adults with Sepsis and Septic Shock
Comparing Hour-1 and 3-Hour Sepsis Treatment Bundles to Improve Survival and Respiratory Outcomes in Adults with Sepsis in the Emergency Department
Studying Muscle Function via L3 CT Scans and Its Link to 3-Month Survival After ICU Stay for Septic Shock Patients
Evaluation of Left and Right Atrial Strain Measurements in Adults with Septic Shock Using Echocardiographic Software
Study on Initial High-Dose Beta-Lactam Antibiotics to Improve Outcomes in Critically Ill Adults with Sepsis